Clinical Trials

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03969446 2026-03-05

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Phase 1 Recruiting

54 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07044544 2026-03-04

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Phase 1 Recruiting

20 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07148947 2026-03-04

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

27 enrolled

Accelerated Phase Myeloproliferative Neoplasm

NCT07283094 2026-03-03

FHD-286

Phase 1 Recruiting

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Classical hematologyMyeloidOther hematologic neoplasm

8 enrolled 9 charts

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01515527 2026-02-06

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

160 enrolled

Phase 2 Active not recruiting

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03164057 2026-01-28

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

206 enrolled

Phase 1 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

16 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT03661307 2026-01-12

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Phase 1/2 Recruiting

73 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05184842 2026-01-05

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

91 enrolled 26 charts

Phase 1 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05564650 2025-12-08

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

6 enrolled

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04188405 2025-11-20

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

20 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT06928662 2025-11-06

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Phase 1/2 Recruiting

36 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02269280 2025-08-07

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

185 enrolled 12 charts

Leukemia, Myelodysplastic Syndromes

NCT02257138 2025-06-08

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

30 enrolled 14 charts

Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT06572631 2025-05-25

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Phase 1 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05766514 2025-04-22

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Phase 2 Withdrawn

Phase EARLY_PHASE1 Recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04187703 2025-04-09

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

20 enrolled

Myelodysplastic Syndromes

NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

67 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06337331 2024-06-14

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Phase 2 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05524857 2024-04-23

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Phase 1 Terminated

2 enrolled

Blast Crisis, Myeloproliferative Disorders

NCT06046313 2024-03-05

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

120 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01812252 2024-02-15

ICT-HCT

50 enrolled 12 charts

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04055844 2023-11-07

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

14 enrolled 20 charts

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04146038 2023-05-24

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

5 enrolled 9 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01834248 2022-07-22

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

9 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02190695 2021-05-19

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

92 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03113071 2021-03-16

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

Phase 1/2 Terminated

1 enrolled 4 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01720225 2020-12-24

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

113 enrolled 10 charts

Leukemia, Myelodysplastic Syndromes

NCT01498445 2020-10-22

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Phase 1/2 Terminated

32 enrolled 16 charts

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02272478 2020-01-23

AML18

Phase 2/3 Unknown

1,600 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02129101 2019-10-30

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

63 enrolled

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT00414310 2019-05-21

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

153 enrolled 8 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01165996 2019-03-04

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Classical hematologyMyeloidOther hematologic neoplasm

25 enrolled 13 charts

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myelomonocytic, Chronic

NCT02076191 2019-02-28

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

49 enrolled

Myeloproliferative Disorders

NCT00075010 2018-11-15

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

54 enrolled

Leukemia, Myelodysplastic Syndromes

NCT00903760 2018-11-15

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

42 enrolled 10 charts

Leukemia, Myelodysplastic Syndromes

NCT02469415 2018-10-16

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Phase 2 Terminated

3 enrolled 6 charts

Leukemia, Myelodysplastic Syndromes

NCT02264873 2018-10-15

Phase I, Dose Escalation Study of Decitabine

LymphoidMyeloidOther hematologic neoplasm

3 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01687400 2018-10-02

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

114 enrolled 12 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01251627 2018-06-25

DECI2009

43 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02121418 2018-04-13

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

Phase NA Completed

12 enrolled 10 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT03356080 2017-11-29

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

Phase 2 Unknown

50 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02564536 2017-05-08

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

Phase 1 Withdrawn